IBRX IMMUNITYBIO
Health Care · Russell 2000
Next earnings: not announced yet
What 8 analyst firms say about IMMUNITYBIO: their latest ratings, price targets and how far the stock is from them. How it works
Analyst window: Latest analyst report within last 1 year
Analyst view · last 1Y
8 rated views · 9 analyst/firm records · 8 firms
Radar score
- Russell 2000 · Top Picks · 6MBelow the Radar threshold of 8071
- Russell 2000 · Safest consensus · 6MBelow the Radar threshold of 8056
Recent analyst activity · last 90 days
Our tracked history has 6 reports on IBRX from 4 analyst firms in the last 90 days (8 firms in the past year).
Comparing each firm's latest target with its previous one: 3 left it unchanged.
No firm's latest available rating differs from its previous one.
Latest observed target change: Jefferies raised its target from $9.00 (set 12 Dec 2025) to $14.00 on 25 Sep 2026.
Last 1 year. Latest opinion per identifiable analyst within the last 1 year. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.
| Firm | Analyst | Latest rating | Report date | Latest target (USD) |
|---|---|---|---|---|
| BTIG | Jeet Mukherjee | Buy | 21 May 2026 | 12.00 USD |
| D Boral Capital | Jason Kolbert | Buy | 5 May 2026 | 23.00 USD |
| Goldman Sachs | Unnamed analyst | Buy | 23 Feb 2026 | — |
| H.C. Wainwright | Andres Y. Maldonado | Buy | 15 Oct 2026 | 15.00 USD |
| Jefferies | Kelly Shi | Buy | 14 Oct 2026 | 14.00 USD |
| Jefferies | Roger Song | Buy | 25 Sep 2026 | 14.00 USD |
| Piper Sandler | Edward A Tenthoff | Buy | 4 Aug 2026 | 16.00 USD |
| Weiss Ratings | Unnamed analyst | — | 6 Oct 2026 | — |
| Data feed RESEARCH | Research Team | Hold | 15 Jun 2026 | Conflicting reports · excluded |
Partial coverage · checked 6 Nov (6 Nov 2026, 04:44 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.